IGC Completes Cohort 2 of its Phase 1 THC-Based Clinical Trial on Alzheimer’s Patients
Cannabis Law Report
JUNE 7, 2021
The Phase 1 clinical trial on Alzheimer’s patients is currently anticipated to conclude during the July through September 2021 timeframe. According to World Health Organization, Alzheimer’s disease is expected to impact approximately 50 million individuals worldwide by 2030. Securities and Exchange Commission (“SEC”) on July 13, 2020.
Let's personalize your content